Conversely to the previous studies, they have shown a significantly increased median percentage of freshly isolated peripheral blood CD4+/CTLA-4+ T cells from both groups of MS patients, which was more marked in RRMS patients [85]. This evidence concerns the gene CD4 and myeloid sarcoma.